Vor Biopharma Inc is a clinical stage cell therapy company. It combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies. The company's products include VOR33. Vor Biopharma Inc is a clinical stage cell therapy company. It combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies. The company's products include VOR33.
Intend to announce updated clinical data from Phase 1/2 VBP301 trial of VCAR33ALLO in the first half of 2025 and updated clinical data from Phase 1/2a VBP101 trial of trem-cel in combination with...
Preliminary data suggests improved relapse-free survival compared to published groups of acute myeloid leukemia (AML) patients at high risk of relapse post-transplantTrem-cel + Mylotarg continue...
CAMBRIDGE, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in a fireside chat and...
Company to present trem-cel + Mylotarg clinical data update at American Society of Hematology (ASH) 2024 annual meetingHan Choi, M.D., LL.M, seasoned healthcare institutional investor, appointed...
期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.2801 | 28.2929292929 | 0.99 | 1.35 | 0.92 | 2561889 | 1.22891205 | CS |
4 | 0.4001 | 45.9885057471 | 0.87 | 1.35 | 0.8 | 1058176 | 1.11005295 | CS |
12 | 0.6023 | 90.1916741539 | 0.6678 | 1.35 | 0.6354 | 669402 | 0.96419725 | CS |
26 | 0.3494 | 37.9493863365 | 0.9207 | 1.35 | 0.6354 | 720517 | 0.92201137 | CS |
52 | -1.1299 | -47.0791666667 | 2.4 | 3.1399 | 0.6354 | 526443 | 1.18272493 | CS |
156 | -10.3999 | -89.116538132 | 11.67 | 12.73 | 0.6354 | 266205 | 2.4119554 | CS |
260 | -40.7499 | -96.9773917182 | 42.02 | 63.62 | 0.6354 | 242771 | 6.21398965 | CS |
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約